Reclipsen
FDA Label NDC 53002-1631

47 label sections · Submitted to the FDA by Rpk Pharmaceuticals, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Rpk Pharmaceuticals, Inc. for the product Reclipsen (NDC 53002-1631). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, pharmacodynamics, pharmacokinetics, indications and usage, contraindications, a. thromboembolism, b. myocardial infarction, c. cerebrovascular diseases, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.